Asthma and COPD Therapies: World Market 2011-2021VisiongainAugust 8, 2011 138 Pages - SKU: VSG6581734 |
|
Conference Documentation: Asthma & COPD
4/15/2013 | published by: SMI Publishing, Ltd
SMi are delighted to present our 9th annual Asthma & COPD event to be held in Central London on Monday 15th & Tuesday 16th of April 2013. Following on from the great success of our
|
read more...
|
$788.78
|
|
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline Review, H1 2013
3/18/2013 | published by: Global Markets Direct
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on
|
read more...
|
$2,000.00
|
|
Asthma – Pipeline Review, H1 2013
3/18/2013 | published by: Global Markets Direct
Asthma – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Asthma - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Asthma, complete with latest
|
read more...
|
$2,000.00
|
|
Asthma Global Clinical Trials Review, H1, 2013
1/31/2013 | published by: GlobalData
Asthma Global Clinical Trials Review, H1, 2013 Summary GlobalData's clinical trial report, “Asthma Global Clinical Trials Review, H1, 2013 provides data on the Asthma clinical trial scenario. This report provides elemental information and data relating to the
|
read more...
|
$2,500.00
|
|
2012 Pharmaceuticals Research Review
12/1/2012 | published by: BCC Research
This review of pharmaceutical market research provides:
Analysis and the future direction of treatments for neurodegenerative (i.e., progressive ataxia and weakness) disorders as the market efforts toward drug and therapy development evolve.
Coverage
|
read more...
|
$950.00
|
|
Chronic Obstructive Pulmonary Disease (COPD) Global Clinical Trials Review, H2, 2012
11/20/2012 | published by: GlobalData
Chronic Obstructive Pulmonary Disease (COPD) Global Clinical Trials Review, H2, 2012 Summary GlobalData's clinical trial report, “Chronic Obstructive Pulmonary Disease (COPD) Global Clinical Trials Review, H2, 2012 provides data on the Chronic Obstructive Pulmonary Disease (COPD) clinical
|
read more...
|
$2,500.00
|
|
Conference Documentation: COPD: Novel Therapeutics and Management Strategies
10/22/2012 | published by: SMI Publishing, Ltd
SMi are proud to present their 4th annual COPD: Novel Therapeutics and Management Strategies conference convening in Central London on Monday 22nd and Tuesday 23rd 2012. Consisting of an industry led programme with academic keynote
|
read more...
|
$788.78
|
|
What are the Market Access Levers and Hurdles Facing Additional LABA/ICS Fixed-Dose Combinations for Asthma in the EU5?
10/12/2012 | published by: Decision Resources
In Europe, four twice-daily, long-acting beta 2 agonist (LABA)/inhaled corticosteroid (ICS) combinations are available as fixed-dose combinations (FDCs) for the maintenance treatment of asthma: Seretide (salmeterol/fluticasone propionate; GlaxoSmithKline), Symbicort (formoterol/budesonide; AstraZeneca), Foster
|
read more...
|
$10,000.00
|
|
How Will Payer and Prescriber Attitudes Toward Emerging LABA/LAMA and LABA/ICS Fixed-Dose Combinations Shape the COPD Markets in the EU5?
11/6/2012 | published by: Decision Resources
Two twice-daily, long-acting beta 2 agonist (LABA)/inhaled corticosteroid (ICS) fixed-dose combinations (FDCs) are approved for the maintenance treatment of COPD in Europe: GlaxoSmithKline’s Seretide (salmeterol/fluticasone propionate) and AstraZeneca’s Symbicort (formoterol/budesonide). Offering
|
read more...
|
$10,000.00
|
|
Market and Product Forecasts: Asthma in China – Market set to fragment as novel therapies launch
7/31/2012 | published by: Datamonitor
Introduction The increasing prevalence of asthma and launch of new therapies will boost the Chinese asthma market (Tier 1 and Tier 2 cities) from $331m in 2012 to $489m by 2021. A number of novel products
|
read more...
|
$11,400.00
|
Research assistance
We can help you find what you need. Call us or write us: Need help in your search?
US: 800.298.5699
Int'l: +1.240.747.3093
Related Markets
Asthma Reports